lunes, 21 de diciembre de 2020

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations | FDA

FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations | FDA

No hay comentarios:

Publicar un comentario